Evidence for Mutation-Specific Selectivity in Non-Small Cell

Total Page:16

File Type:pdf, Size:1020Kb

Evidence for Mutation-Specific Selectivity in Non-Small Cell Acta Pharmacologica Sinica (2015) 36: 291–297 npg © 2015 CPS and SIMM All rights reserved 1671-4083/15 $32.00 www.nature.com/aps Review The RAS-RAL axis in cancer: evidence for mutation- specific selectivity in non-small cell lung cancer Sunny GUIN1, 2, Dan THEODORESCU1, 2, 3, * 1Department of Surgery, University of Colorado, Aurora, CO 80045, USA; 2Department of Pharmacology, University of Colorado, Aurora, CO 80045, USA; 3University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA Activating RAS mutations are common in human tumors. These mutations are often markers for resistance to therapy and subsequent poor prognosis. So far, targeting the RAF-MEK-ERK and PI3K-AKT signaling pathways downstream of RAS is the only promising approach in the treatment of cancer patients harboring RAS mutations. RAL GTPase, another downstream effector of RAS, is also considered as a therapeutic option for the treatment of RAS-mutant cancers. The RAL GTPase family comprises RALA and RALB, which can have either divergent or similar functions in different tumor models. Recent studies on non-small cell lung cancer (NSCLC) have showed that different RAS mutations selectively activate specific effector pathways. This observation requires broader validation in other tumor tissue types, but if true, will provide a new approach to the treatment of RAS-mutant cancer patients by targeting specific downstream RAS effectors according to the type of RAS mutation. It also suggests that RAL GTPase inhibition will be an important treatment strategy for tumors harboring RAS glycine to cysteine (G12C) or glycien to valine (G12V) mutations, which are commonly found in NSCLC and pancreatic cancer. Keywords: RAS; RAL; RAS mutation; RALBP1; non-small cell lung cancer Acta Pharmacologica Sinica (2015) 36: 291–297; doi: 10.1038/aps.2014.129; published online 5 Jan 2015 RAS GTPase overview RAS is the most extensively studied GTPase[1]. It is known to regulate various cellular functions, including proliferation, survival, growth, migration, differentiation and cytoskeletal dynamics[2–4] (Figure 1). Not coincidentally, increased activi- ties of all of these processes are required by tumor cells to promote tumor growth. Activating oncogenic RAS mutations lead to treatment resistance in various tumor models and poor patient outcomes[3, 5–9]. Three human RAS genes have been identified: HRAS, KRAS, and NRAS[1, 2]. These encode the related proteins HRAS, KRAS and NRAS, respectively, of 189 amino acids in length[1, 4]. KRAS exists as two isoforms, 4A and 4B, which are generated by alternative exon splicing[10]. These different RAS genes are well known to have differential cellular specificities and intrinsic transforming potentials[3, 4, 10]. In normal cells, RAS proteins act as molecular switches for critical cellular functions. RAS proteins are activated Figure 1. by upstream receptors such as receptor tyrosine kinases RAS GTPase activation and downstream signaling. The cartoon shows the mechanism of RAS GTPase activation by upstream stimuli and numerous downstream effectors stimulated by activated RAS. RAS * To whom correspondence should be addressed. regulates critical cellular functions through these effectors. Constitutive E-mail [email protected] RAS activation due to mutations leads to protumorigenic signaling through Received 2014-08-07 Accepted 2014-10-30 these effectors. npg www.nature.com/aps Guin S et al 292 (RTKs), G-protein coupled receptors (GPCRs) and serpen- naling pathways. For example, mutant KRAS with either a tine and cytokine receptors[1, 4, 11]. RAS protein activity is glycine to cysteine (G12C) or glycine to valine (G12V) muta- tightly regulated by Guanine Nucleotide Exchange Factors tion at codon 12 preferentially binds to RAL guanine nucleo- (GEFs) and GTPase Activating Proteins (GAPs). Constitu- tide dissociation stimulator (RALGDS), a RAL GTPase-specific tive activation of the RAS protein, in which RAS is unable to GEF, whereas KRAS harboring a glycine to aspartate mutation hydrolyze GTP, leads to cancer and other diseases[1, 9, 12]. Acti- at codon 12 (G12D) has higher affinity for phosphatidylino- vating RAS mutations have been observed in 30% of human sitol 3-kinase (PI3K)[20]. These recent studies have brought to tumors[2, 13]; KRAS is the most commonly mutated isoform, light the need to clarify the impact of such KRAS mutations on mutated in 25%–30% of human cancers[3, 13]. KRAS mutations the RAL GTPase signaling pathway. are dominant in colorectal cancer (40%–45%), non-small cell lung cancer (NSCLC) (15%–40%) and pancreatic carcinoma The RAL GTPase family and effectors (69%–95%)[2, 3] and are associated with poor patient outcomes RAL GTPase falls under the RAS family of GTPases. RAL and treatment responses in these malignancies[2, 3]. NRAS and shares a high degree of sequence similarity with the three RAS HRAS mutations are less common (8% and 3% of all tumors, genes, hence the name RAL (RAS-like)[1]. The RAL GTPase respec tively)[2, 13], with melanoma harboring the most NRAS sub-family comprises the two isoforms RALA and RALB, mutations at 20%–30%[2, 13]. which share high sequence homology[21]. Approximately 85% Activating mutations occur at codons 12, 13, and 61, which of the amino acid sequences of these two isoforms are identi- are within the GTPase catalytic domain, in all three RAS iso- cal[21]. RAL GTPase can be activated by six GEFs (RALGEFs), forms[14]. Approximately 80% of KRAS mutations are found RALGDS, RGL, RGL2/Rlf, RGL3, RALGPS1, and RALGPS2, in codon 12, whereas approximately 60% of NRAS mutations and inactivated by two GAPs, RALGAP1, and RALGAP2[22, 23]. are found in codon 61, with 35% in codon 12[2, 14]. HRAS muta- Four RALGEFs (RALGDS, RGL, RGL2, and RGL3) are known tions are equally divided between codons 12 and 61[2, 14]. All to directly interact with the effector binding region of GTP- of these activating mutations inhibit RAS GTPase activity by bound RAS and are thus important for RAS-mediated tumori- preventing GAP-stimulated GTP hydrolysis of GTP-bound genesis[22]. RALGEFs and RAL play a dominant role in the activated RAS. RAS-mediated transformation of several different immor- Approximately 20 downstream effectors bind to RAS-GTP talized human cell lines, as well as in a RAS-driven tumor and trigger signaling. RAS drives tumor growth via a number model[24, 25]. of prominent pathways, including the following: RAF-MEK- RAL proteins mediate various cellular activities, including ERK[15, 16]; p110 catalytic subunits (p110α, β, γ, and δ) of class I filopodia formation/membrane ruffling, glycolysis, autoph- PI3K; TIAM1, a small RAC GTPase-specific GEF; RAL-specific agy, secretion, the maintenance of polarity, apoptosis and GEFs (RALGDS, RGL, RGL2, and RGL3); and phospholipase transcription[21, 26] (Figure 2). Alterations to these activities can C epsilon[1, 2, 16]. lead to tumor invasion, metastasis, altered cellular energy lev- els, proliferative signaling and resistance to cell death. These RAS mutation and cancer therapeutics activities are mediated by effectors that interact with activated Devising an effective treatment strategy for patients with RAS (GTP-bound) RAL[22]. Of all the RAL effectors, the most exten- mutations has been a major challenge[2, 17]. However, recent sively studied are RALBP1 and the members of the exocyst attempts have been promising[17, 18]. RNA interference is an complex Sec5 and Exo84[26]. Other RAL effectors include Fila- interesting approach but has many technical hurdles, includ- min, PLD1 and ZONAB[26]. ing the lack of an efficient delivery system, poor uptake and RALBP1 has GAP activity for RAC/CDC42 proteins. In low gene silencing efficiency[2]. The inhibition of RAS mem- this way, RALBP1 is important for actin dynamics, filopodia brane localization via the inhibition of RAS farnesylation has formation and membrane ruffling[1, 26, 27], thereby contributing been investigated, but this approach has failed to materialize to cancer cell adhesion, invasion and migration. RALBP1 is into a therapeutic strategy due to several limitations, including critical for the migration of bladder and prostate cancer cells, toxicity, and mainly the appearance of a compensatory mecha- which is partly independent of its interaction with RAL[28]. nism via geranylgeranylation[2, 8, 19]. RALBP1 is also important for endocytosis, including receptor- So far, the only approach that has shown promise in treat- mediated endocytosis of proteins such as epidermal growth ing cancer patients with RAS mutations is the targeting of its factor receptor, insulin receptor and transferrin receptor, downstream signaling cascades such as RAF-MEK-ERK and through its interactions with POB1, Reps1 and AP2[29–31]. The PI3K-AKT[2, 8, 16, 19]. Targeting these two pathways either sepa- involvement of RALBP1 in receptor endocytosis points to the rately or together is beneficial in preventing in vitro and in vivo prominence of RAL in signal transduction by these receptors, progression of tumors harboring a RAS mutation[2]. Currently, which regulate various cellular processes such as survival clinical trials are being conducted to study the therapeutic and proliferation[32, 33]. RALBP1 has also been identified as a effects of MEK and PI3K inhibitors in cancer patients harbor- non-ABC transporter that causes resistance to chemothera- ing RAS mutations[2]. However, a wrinkle in this approach peutic drugs[34]. RALBP1 is known to cause resistance to has appeared. Recent studies have shown that different KRAS anthracycline derivatives such as doxorubicin and glutathione mutations preferentially activate different downstream sig- conjugates by increasing their efflux from cells in an ATP- Acta Pharmacologica Sinica www.chinaphar.com npg Guin S et al 293 Figure 2. RAL effectors and their functions. Upon activation, RAL GTPase regulates numerous biological processes through its effectors. Abnormal regulation of these biological processes by activated RAL leads to protumorigenic biological outcomes. The various dotted lines show the cellular processes regulated by each RAL effector and the corresponding biological outcomes.
Recommended publications
  • Localization of Ralb Signaling at Endomembrane Compartments and Its Modulation by Autophagy Received: 14 January 2019 Manish Kumar Singh1,2, Alexandre P
    www.nature.com/scientificreports Corrected: Publisher Correction OPEN Localization of RalB signaling at endomembrane compartments and its modulation by autophagy Received: 14 January 2019 Manish Kumar Singh1,2, Alexandre P. J. Martin1,2, Carine Jofre 3, Giulia Zago1,2, Accepted: 30 May 2019 Jacques Camonis1,2, Mathieu Coppey1,4 & Maria Carla Parrini1,2 Published online: 20 June 2019 The monomeric GTPase RalB controls crucial physiological processes, including autophagy and invasion, but it still remains unclear how this multi-functionality is achieved. Previously, we reported that the RalGEF (Guanine nucleotide Exchange Factor) RGL2 binds and activates RalB to promote invasion. Here we show that RGL2, a major activator of RalB, is also required for autophagy. Using a novel automated image analysis method, Endomapper, we quantifed the endogenous localization of the RGL2 activator and its substrate RalB at diferent endomembrane compartments, in an isogenic normal and Ras-transformed cell model. In both normal and Ras-transformed cells, we observed that RGL2 and RalB substantially localize at early and recycling endosomes, and to lesser extent at autophagosomes, but not at trans-Golgi. Interestingly the use of a FRET-based RalB biosensor indicated that RalB signaling is active at these endomembrane compartments at basal level in rich medium. Furthermore, induction of autophagy by nutrient starvation led to a considerable reduction of early and recycling endosomes, in contrast to the expected increase of autophagosomes, in both normal and Ras-transformed cells. However, autophagy mildly afected relative abundances of both RGL2 and RalB at early and recycling endosomes, and at autophagosomes. Interestingly, RalB activity increased at autophagosomes upon starvation in normal cells.
    [Show full text]
  • The Role of Rala and Ralb in Cancer Samuel C
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School 4-7-2008 The Role of RalA and RalB in Cancer Samuel C. Falsetti University of South Florida Follow this and additional works at: https://scholarcommons.usf.edu/etd Part of the American Studies Commons Scholar Commons Citation Falsetti, Samuel C., "The Role of RalA and RalB in Cancer" (2008). Graduate Theses and Dissertations. https://scholarcommons.usf.edu/etd/232 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. The Role of RalA and RalB in Cancer By Samuel C. Falsetti A dissertation submitted in partial fulfillment Of the requirements for the degree of Doctor of Philosophy Department of Molecular Medicine College of Medicine University of South Florida Major Professor: Saïd M. Sebti, Ph.D. Larry P. Solomonson, Ph.D. Gloria C. Ferreira, Ph.D. Srikumar Chellapan, Ph.D. Gary Reuther, Ph.D. Douglas Cress, Ph.D. Date of Approval: April 7th, 2008 Keywords: Ras, RACK1, Geranylgeranyltransferase I inhibitors, ovarian cancer, proteomics © Copyright 2008, Samuel C. Falsetti Dedication This thesis is dedicated to my greatest supporter, my wife. Without her loving advice and patience none of this would be possible. Acknowledgments I would like to extend my sincere gratitude to my wife, Nicole. She is the most inspirational person in my life and I am honored to be with her; in truth, this degree ought to come with two names printed on it.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]
  • RAP2 Mediates Mechanoresponses of the Hippo Pathway Zhipeng Meng1, Yunjiang Qiu2,3, Kimberly C
    LETTER https://doi.org/10.1038/s41586-018-0444-0 RAP2 mediates mechanoresponses of the Hippo pathway Zhipeng Meng1, Yunjiang Qiu2,3, Kimberly C. Lin1, Aditya Kumar4, Jesse K. Placone4, Cao Fang1, Kuei-Chun Wang4,5, Shicong Lu1, Margaret Pan1, Audrey W. Hong1, Toshiro Moroishi1,6,7, Min Luo1,8, Steven W. Plouffe1, Yarui Diao2, Zhen Ye2, Hyun Woo Park1,9, Xiaoqiong Wang10, Fa-Xing Yu11, Shu Chien4,5, Cun-Yu Wang12, Bing Ren2,13, Adam J. Engler4 & Kun-Liang Guan1* Mammalian cells are surrounded by neighbouring cells and Extended Data Fig. 1b). Expression of the YAP and TAZ target extracellular matrix (ECM), which provide cells with structural genes CTGF, CYR61, and ANKRD1 was repressed by low stiffness in support and mechanical cues that influence diverse biological wild-type cells, but not in RAP2-KO cells (Fig. 1f). Similar results were processes1. The Hippo pathway effectors YAP (also known as YAP1) observed in human mesenchymal stem cells (Extended Data Fig. 1c–e), and TAZ (also known as WWTR1) are regulated by mechanical in which RAP2 deletion suppressed differentiation into adipocytes cues and mediate cellular responses to ECM stiffness2,3. Here we (Extended Data Fig. 1f, g). In luminal breast cancer MCF7 cells, identified the Ras-related GTPase RAP2 as a key intracellular ECM stiffness modulated localization of YAP and TAZ in a RAP2- signal transducer that relays ECM rigidity signals to control dependent manner, whereas the basal type MDA-MB-468 cells showed mechanosensitive cellular activities through YAP and TAZ. constitutively cytoplasmic localization of YAP and TAZ regardless RAP2 is activated by low ECM stiffness, and deletion of RAP2 of stiffness (Extended Data Fig.
    [Show full text]
  • SHOC2–MRAS–PP1 Complex Positively Regulates RAF Activity and Contributes to Noonan Syndrome Pathogenesis
    SHOC2–MRAS–PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis Lucy C. Younga,1, Nicole Hartiga,2, Isabel Boned del Ríoa, Sibel Saria, Benjamin Ringham-Terrya, Joshua R. Wainwrighta, Greg G. Jonesa, Frank McCormickb,3, and Pablo Rodriguez-Vicianaa,3 aUniversity College London Cancer Institute, University College London, London WC1E 6DD, United Kingdom; and bHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158 Contributed by Frank McCormick, September 18, 2018 (sent for review November 22, 2017; reviewed by Deborah K. Morrison and Marc Therrien) Dephosphorylation of the inhibitory “S259” site on RAF kinases CRAF/RAF1 mutations are also frequently found in NS and (S259 on CRAF, S365 on BRAF) plays a key role in RAF activation. cluster around the S259 14-3-3 binding site, enhancing CRAF ac- The MRAS GTPase, a close relative of RAS oncoproteins, interacts tivity through disruption of 14-3-3 binding (8) and highlighting the with SHOC2 and protein phosphatase 1 (PP1) to form a heterotri- key role of this regulatory step in RAF–ERK pathway activation. meric holoenzyme that dephosphorylates this S259 RAF site. MRAS is a very close relative of the classical RAS oncoproteins MRAS and SHOC2 function as PP1 regulatory subunits providing (H-, N-, and KRAS, hereafter referred to collectively as “RAS”) the complex with striking specificity against RAF. MRAS also func- and shares most regulatory and effector interactions as well as tions as a targeting subunit as membrane localization is required transforming ability (9–11). However, MRAS also has specific for efficient RAF dephosphorylation and ERK pathway regulation functions of its own, and uniquely among RAS family GTPases, it in cells.
    [Show full text]
  • Phosphorylation of Ralb Is Important for Bladder Cancer Cell Growth and Metastasis
    Published OnlineFirst October 12, 2010; DOI: 10.1158/0008-5472.CAN-10-0952 Published OnlineFirst on October 12, 2010 as 10.1158/0008-5472.CAN-10-0952 Therapeutics, Targets, and Chemical Biology Cancer Research Phosphorylation of RalB Is Important for Bladder Cancer Cell Growth and Metastasis Hong Wang1, Charles Owens1, Nidhi Chandra1, Mark R. Conaway2, David L. Brautigan3,4, and Dan Theodorescu5 Abstract RalA and RalB are monomeric G proteins that are 83% identical in amino acid sequence but have paralogue- specific effects on cell proliferation, metastasis, and apoptosis. Using in vitro kinase assays and phosphosite- specific antibodies, here we show phosphorylation of RalB by protein kinase C (PKC) and RalA by protein kinase A. We used mass spectrometry and site-directed mutagenesis to identify S198 as the primary PKC phosphorylation site in RalB. Phorbol ester [phorbol 12-myristate 13-acetate (PMA)] treatment of human blad- der carcinoma cells induced S198 phosphorylation of stably expressed FLAG-RalB as well as endogenous RalB. PMA treatment caused RalB translocation from the plasma membrane to perinuclear regions in a S198 phos- phorylation–dependent manner. Using RNA interference depletion of RalB followed by rescue with wild-type RalB or RalB(S198A) as well as overexpression of wild-type RalB or RalB(S198A) with and without PMA stimulation, we show that phosphorylation of RalB at S198 is necessary for actin cytoskeletal organization, anchorage-independent growth, cell migration, and experimental lung metastasis of T24 or UMUC3 human bladder cancer cells. In addition, UMUC3 cells transfected with a constitutively active RalB(G23V) exhibited enhanced subcutaneous tumor growth, whereas those transfected with phospho-deficient RalB(G23V-S198A) were indistinguishable from control cells.
    [Show full text]
  • Identification of the Rassf3 Gene As a Potential Tumor Suppressor
    Clemson University TigerPrints All Dissertations Dissertations 12-2006 Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/ neu Transgenic Mice Isabelle Jacquemart Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Part of the Microbiology Commons Recommended Citation Jacquemart, Isabelle, "Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice" (2006). All Dissertations. 26. https://tigerprints.clemson.edu/all_dissertations/26 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. IDENTIFICATION OF THE Rassf3 GENE AS A POTENTIAL TUMOR SUPPRESSOR RESPONSIBLE FOR THE RESISTANCE TO MAMMARY TUMOR DEVELOPMENT IN MMTV/neu TRANSGENIC MICE A Dissertation Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Microbiology by Isabelle C. Jacquemart December 2006 Accepted by: Dr. Wen Y. Chen, Committee Chair Dr. Charles D. Rice Dr. Lyndon L. Larcom Dr. Lesly Temesvari i ABSTRACT The MMTV/neu transgenic mouse line is a well-documented animal model for studying HER2/neu-related breast cancer. It has been reported that a small percentage, approximately 20%, of the virgin female MMTV/neu mice seems resistant to the development of mammary gland adenoma, despite the overexpression of the neu oncogene. To identify the factors that are responsible for the tumor resistance in these MMTV/neu female transgenic mice, comparative genetic profiling was used to screen the alterations in gene expression in the mammary gland.
    [Show full text]
  • The Small G-Protein Rala Promotes Progression and Metastasis of Triple- Negative Breast Cancer Katie A
    Thies et al. Breast Cancer Research (2021) 23:65 https://doi.org/10.1186/s13058-021-01438-3 RESEARCH ARTICLE Open Access The small G-protein RalA promotes progression and metastasis of triple- negative breast cancer Katie A. Thies1,2, Matthew W. Cole1,2, Rachel E. Schafer1,2, Jonathan M. Spehar1,2, Dillon S. Richardson1,2, Sarah A. Steck1,2, Manjusri Das1,2, Arthur W. Lian1,2, Alo Ray1,2, Reena Shakya1,3, Sue E. Knoblaugh4, Cynthia D. Timmers5,6, Michael C. Ostrowski5,7, Arnab Chakravarti1,2, Gina M. Sizemore1,2 and Steven T. Sizemore1,2* Abstract Background: Breast cancer (BC) is the most common cancer in women and the leading cause of cancer-associated mortality in women. In particular, triple-negative BC (TNBC) has the highest rate of mortality due in large part to the lack of targeted treatment options for this subtype. Thus, there is an urgent need to identify new molecular targets for TNBC treatment. RALA and RALB are small GTPases implicated in growth and metastasis of a variety of cancers, although little is known of their roles in BC. Methods: The necessity of RALA and RALB for TNBC tumor growth and metastasis were evaluated in vivo using orthotopic and tail-vein models. In vitro, 2D and 3D cell culture methods were used to evaluate the contributions of RALA and RALB during TNBC cell migration, invasion, and viability. The association between TNBC patient outcome and RALA and RALB expression was examined using publicly available gene expression data and patient tissue microarrays. Finally, small molecule inhibition of RALA and RALB was evaluated as a potential treatment strategy for TNBC in cell line and patient-derived xenograft (PDX) models.
    [Show full text]
  • Genetic Deletion of RALA and RALB Small Gtpases Reveals Redundant Functions in Development and Tumorigenesis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Current Biology 22, 2063–2068, November 6, 2012 ª2012 Elsevier Ltd All rights reserved http://dx.doi.org/10.1016/j.cub.2012.09.013 Report Genetic Deletion of RALA and RALB Small GTPases Reveals Redundant Functions in Development and Tumorigenesis Pascal Peschard,1 Afshan McCarthy,1 (Figures 1A and 1B) and loss of RALB proteins in tissues of Vale´rie Leblanc-Dominguez,1 Maggie Yeo,1 adult mice (Figure 1C). The expression of RALB proteins was Sabrina Guichard,1 Gordon Stamp,2 unchanged in Rala null cells and vice versa. and Christopher J. Marshall1,* To investigate the role of RALA in embryonic development, 1Oncogene Team, Division of Cancer Biology, Institute of we examined embryos from Rala+/2 intercrosses. Between Cancer Research, London SW3 6JB, UK embryonic day 10.5 (E10.5) and E19.5, we observed that 10 2Department of Histopathology, Royal Marsden Hospital, out of 33 of the Rala null embryos displayed exencephaly London SW3 6JJ, UK (Figures 1E and 1F), a condition caused by a failure of closure of the neural tube along the hindbrain region [15]. We also observed exencephaly in Rala null embryos generated from Summary a gene-trap embryonic stem (ES) clone (Figures 1G and S1E– S1I). To examine whether RALA and RALB have overlapping RAL small GTPases, encoded by the Rala and Ralb genes, functions in neural tube closure, we generated compound are members of the RAS superfamily of small GTPases and mutants: 14 of 14 Rala2/2;Ralb+/2 embryos displayed a severe can act as downstream effectors of RAS [1].
    [Show full text]
  • Targeting the Ras-Ral Effector Pathway for Cancer Treatment
    TARGETING THE RAS-RAL EFFECTOR PATHWAY FOR CANCER TREATMENT Leanna R. Gentry A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2015 Approved by: Adrienne Cox Channing Der Lee Graves Klaus Hahn Gary Johnson ©2015 Leanna R. Gentry ALL RIGHTS RESERVED ii ABSTRACT LEANNA R. GENTRY: Targeting the Ras-Ral effector pathway for cancer treatment (Under the direction of Channing J. Der) The RAS oncogene is the most frequently mutated gene in human cancers, and this activated Ras oncoprotein has been shown to be required for both cancer initiation and maintenance. Great strides have been made in understanding Ras signaling in cancer since the discovery of its involvement in human cancers in 1982, with numerous Ras effector pathways and modes of Ras regulation having been identified as contributing to Ras-driven oncogenesis. However, there has been limited success in developing strategies for therapeutically targeting Ras-driven oncogenesis. One effort that has gained popularity in recent years is the inhibition of Ras effector signaling. The Ral (Ras-like) small GTPases, discovered shortly after Ras in an attempt to identify RAS-related genes, are activated downstream of Ras by Ral guanine nucleotide exchange factors (RalGEFs). The Ral family members have since emerged as critical regulators of key cellular processes and, importantly, have been characterized as playing a role in tumorigenesis and invasion of multiple cancer types. Interestingly, divergent roles for RalA and RalB are often observed in within a cancer.
    [Show full text]
  • The RAS–Effector Interaction As a Drug Target Adam B
    Published OnlineFirst January 6, 2017; DOI: 10.1158/0008-5472.CAN-16-0938 Cancer Review Research The RAS–Effector Interaction as a Drug Target Adam B. Keeton1,2, E. Alan Salter3, and Gary A. Piazza1,2 Abstract About a third of all human cancers harbor mutations in one direct inhibitors of RAS proteins. Here, we review this evidence of the K-, N-, or HRAS genes that encode an abnormal RAS with a focus on compounds capable of inhibiting the interac- protein locked in a constitutively activated state to drive malig- tion of RAS proteins with their effectors that transduce the nant transformation and tumor growth. Despite more than signals of RAS and that drive and sustain malignant transfor- three decades of intensive research aimed at the discovery of mation and tumor growth. These reports of direct-acting RAS RAS-directed therapeutics, there are no FDA-approved drugs inhibitors provide valuable insight for further discovery and that are broadly effective against RAS-driven cancers. Although development of clinical candidates for RAS-driven cancers RAS proteins are often said to be "undruggable," there is involving mutations in RAS genes or otherwise activated RAS mounting evidence suggesting it may be feasible to develop proteins. Cancer Res; 77(2); 221–6. Ó2017 AACR. Introduction Activating mutations at codons 12, 13, or 61 of KRAS occur de novo in approximately one third of all human cancers and are Cancer is a leading cause of death in the developed world with especially prevalent in pancreatic, colorectal, and lung tumors. more than one million people diagnosed and more than 500,000 These mutations affect the P-loop and switch-2 regions of the deaths per year in the United States alone.
    [Show full text]
  • Exocyst Inactivation in Urothelial Cells Disrupts Autophagy and Activates Non-Canonical
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.05.451173; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Exocyst Inactivation in Urothelial Cells Disrupts Autophagy and Activates non-canonical NF-κB Michael A. Ortega1,2, Ross K. Villiger2, Malia Harrison-Chau2, Suzanna Lieu2, Kadee-Kalia Tamashiro2, Amanda J. Lee2,3, Brent A. Fujimoto2, Geetika Y. Patwardhan2, Joshua Kepler2 & Ben Fogelgren*2 1 Center for Biomedical Research at The Queen’s Medical Center, Honolulu, Hawaii 96813; 2 Department of Anatomy, Biochemistry and Physiology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii 96813; 3 Math and Sciences Department, Kapiolani Community College, Honolulu, Hawaii 96816. *Corresponding Author: Ben Fogelgren Email address: [email protected] Keywords: autophagy / exocyst / Fn14 / NF-κB / urothelium 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.07.05.451173; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Ureter obstruction is a highly prevalent event during embryonic development and is a major cause of pediatric kidney disease. We have reported that ureteric bud-specific ablation of the exocyst Exoc5 subunit in late-murine gestation results in failure of urothelial stratification, cell death, and complete ureter obstruction. However, the mechanistic connection between disrupted exocyst activity, urothelial cell death, and subsequent ureter obstruction was unclear. Here, we report that inhibited urothelial stratification does not drive cell death during ureter development.
    [Show full text]